Product Name:methyl 1-aminocyclohexane-1-carboxylate

IUPAC Name:methyl 1-aminocyclohexane-1-carboxylate

CAS:4507-57-7
Molecular Formula:C8H15NO2
Purity:95%+
Catalog Number:CM108010
Molecular Weight:157.21

Packing Unit Available Stock Price($) Quantity
CM108010-10g in stock ĽŢǯ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:4507-57-7
Molecular Formula:C8H15NO2
Melting Point:-
Smiles Code:O=C(C1(N)CCCCC1)OC
Density:
Catalog Number:CM108010
Molecular Weight:157.21
Boiling Point:209.9°C at 760 mmHg
MDL No:MFCD08686793
Storage:Keep in a tight container and store at 2°C~8°C,protect from light

Category Infos

Amino Acids and Peptides
Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.
amino acids wholesale
if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!
Cyclohexanes
Cyclohexane is an organic compound with a chemical formula C6H12. It is a colorless liquid with a pungent odor, insoluble in water, and soluble in most organic solvents such as ethanol, ether, benzene, and acetone. Cyclohexyl fragments are a common structure in both natural and synthetic drugs. It can be used as both core structure and part of achiral side chain.

Column Infos

INX-315
Incyclix Bio announces FDA clearance of investigational new drug application for INX-315 in patients with advanced or metastatic cancer. INX-315 is a novel, potent and selective inhibitor of Cyclin-dependent kinase 2 (CDK2) with compelling pre-clinical efficacy and safety data.
CDK2 is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i).